PBLS compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

PBLSParabilis Medicines, Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

PBLSParabilis Medicines, Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

PBLS1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−4.65%—

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

= impliedPBLS realized, solidLLY realized, hatchedOne scale, both sides: full bar = 11%× = |realized| ÷ impliedSource: market data

Q1 FY26

±5.3%

▲+9.80%

×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

PBLSParabilis Medicines, Inc.

27.87▼−8.19%· post 27.87

Mkt cap$806.0MRevenue$148,000Q2 FY26Revenue—

LLYELI Lilly & Co

1,371.32▼−3.29%· post 1,363.77

ClosedNov 5 '26

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

ClosedNov 5 '26

PBLSParabilis Medicines, Inc.

LLYELI Lilly & Co

27.87▼−8.19%post 27.87

Price

1,371.32▼−3.29%post 1,363.77

$806.0M

Mkt cap

$1.2T

Q2 FY26$148,000

Revenue

$24.4BQ3 FY26

—

Revenue

$65.2BFY25

PBLS27.87▼−8.19%vsLLY1,371.32▼−3.29%ClosedNov 5 '26